An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of 3 fixed doses of
JNJ-37822681 compared with placebo (an inactive substance that is compared with a drug to
test if the drug has a real effect in a clinical trial) after 6 weeks treatment and
olanzapine after 12 weeks treatment in participants with schizophrenia (psychiatric disorder
with symptoms of emotional instability, detachment from reality, often with delusions and
hallucinations, and withdrawal into the self).
Phase:
Phase 2
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.